Using a new oral medication to treat endometriosis and its pain
Phase II- Repurposing CRH antagonists for the treatment of endometriosis
This study is testing a new pill to help women with endometriosis manage their pain and reduce the need for surgeries, making life a little easier for those dealing with this challenging condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sur180 Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Mcallen, United States) |
| Project ID | NIH-11183203 on NIH RePORTER |
What this research studies
This research focuses on developing an oral medication aimed at managing endometriosis and alleviating associated pain. The approach seeks to reduce the need for repeated surgeries, which are common for women suffering from this condition. Endometriosis affects a significant number of women and often leads to chronic pain and infertility. The research builds on promising results from earlier studies that showed the drug candidate could effectively reduce pain and disease markers without disrupting hormonal cycles.
Who could benefit from this research
Good fit: Ideal candidates for this research are women of childbearing age who are diagnosed with endometriosis and experience chronic pain associated with the condition.
Not a fit: Patients who do not have endometriosis or those who are not experiencing significant pain related to the condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that alleviates pain and slows the progression of endometriosis, potentially improving quality of life for many women.
How similar studies have performed: Previous studies have shown success with similar approaches in managing endometriosis pain, indicating potential for this new treatment to be effective.
Where this research is happening
Mcallen, United States
- Sur180 Therapeutics, LLC — Mcallen, United States (Active)
Researchers
- Principal investigator: Torres-Reveron, Annelyn — Sur180 Therapeutics, LLC
- Study coordinator: Torres-Reveron, Annelyn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.